PetVivo Holdings reported fiscal 2026 results highlighting key milestones: Health Canada authorized its Spryng with OsteoCushion Technology for veterinary use, enabling Canadian commercialization by July. The company also launched a public beta of its AI-powered AgenticPet platform, enhancing pet healthcare with 97% diagnostic accuracy and reducing veterinary customer acquisition costs significantly. Additionally, PetVivo acquired PiezoBioMembrane, advancing its biomaterials R&D for animal and human medical applications. These developments position PetVivo for growth with new products, expanded markets, and recurring revenue streams from AI and medical devices.
Plum Acquisition Corp. IV has postponed its extraordinary general meeting of shareholders from July 2 to July 10, 2026, to allow more time for shareholder engagement. Consequently, the deadline for shareholders to submit redemption requests has been ...
The U.S. Supreme Court ruled in Chatrie v. U.S. that government collection of location data via geofence warrants constitutes a search under the Fourth Amendment. This decision overturns a lower court ruling and requires further review of whether the...
DBV Technologies is preparing to submit a Biologics License Application (BLA) for its VIASKIN® Peanut patch aimed at children aged 4 to 7 years. The company has engaged in detailed discussions with the FDA to ensure a thorough and efficient review pr...
Bron, a self-custody crypto wallet provider, has partnered with Noah, a global stablecoin payments infrastructure company, to enable seamless on- and off-ramp access for stablecoins. This integration allows Bron users to easily fund and withdraw from...
Institutional investors have decreased their exposure to Bitcoin and Ethereum ETFs, signaling a shift in their cryptocurrency investment strategies. Despite this reduction, they continue to increase their investments in XRP and HYPE wrappers, which a...
